First German Patient Enrolled Pushes Rox Medical Past Halfway Point in CONTROL-HTN Trial
September 27, 2013 — Rox Medical has crossed the halfway point in the CONTROL-HTN international, multi-center, randomized controlled hypertension trial. The milestone was met with the enrollment of the first patient from Prof. Markus van der Giet and Prof. Walter Zidek of the Charite Hospital, Benjamin Franklin Campus, Berlin. The CONTROL-HTN trial is evaluating the Rox Flow procedure — creating a small connection between artery and vein in the upper leg - for the treatment of resistant hypertension.
Rox Medical's Flow procedure is a minimally invasive, catheter procedure to place a small coupler between the artery and vein in the upper leg. The procedure reduces peripheral vascular resistance by diverting some of the higher-pressure arterial blood to the low pressure and highly compliant venous system; essentially restoring some of the lost compliance back into the vascular system.
The Rox Flow procedure for hypertension is not approved for use in the United States.
For more information: www.roxmedical.com
More like this
- Rox Medical Enrolls First U.K. Patients in CONTROL-HTN Hypertension Trial
- Rox Medical
- Renal Denervation Technology from St. Jude Medical Demonstrates Significant Reduction in Blood Pressure
- St. Jude Medical Receives CE Mark for Faster Renal Denervation System
- St. Jude Medical Initiates First U.S. Clinical Study of the EnligHTN Renal Denervation System